


SU3327

## Chemical Properties

CAS No. : 40045-50-9  
 Formula: C<sub>5</sub>H<sub>3</sub>N<sub>5</sub>O<sub>2</sub>S<sub>3</sub>  
 Molecular Weight: 261.3  
 Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year  
 Actual storage temperature shall be subject to the COA.



## Biological Description

Description	SU3327 (halicin) is a potent, selective and substrate-competitive inhibitor of JNK(IC <sub>50</sub> of 0.7 μM).
Targets(IC <sub>50</sub> )	JNK
In vitro	TNF-α stimulated phosphorylation of c-Jun in HeLa cells inhibited by SU3327 with EC <sub>50</sub> of 6.23 μM[1]. SU3327 (25 nM) pretreatment of human-derived cerebral microvascular endothelial cells (hCMEC/D3) effectively reduces LPS-induced polymorphonuclear leukocytes (PMN) rolling/adhesion to hCMEC/D3, prevents activation of AP-1, and significantly reduces expression of VCAM-1[3].
In vivo	In male BKS.Cg-+Leprdb/+Leprdb/OlaHsd db/db mice, SU3327 (25 mg/kg; intraperitoneal injection; ) treatment possesses the ability to restore insulin sensitivity in mice models of diabetes[1]. SU3327 has favorable microsomal and plasma stability (T <sub>1/2</sub> = 27 min)[1].

## Solubility Information

Solubility	DMSO: 83.3 mg/mL (318.79 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween-80+45% Saline: 2.5 mg/mL (9.57 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

### Preparing Stock Solutions

---

	<b>1mg</b>	<b>5mg</b>	<b>10mg</b>
1 mM	3.827 mL	19.1351 mL	38.2702 mL
5 mM	0.7654 mL	3.827 mL	7.654 mL
10 mM	0.3827 mL	1.9135 mL	3.827 mL
50 mM	0.0765 mL	0.3827 mL	0.7654 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

- De SK, et al. Design, synthesis, and structure-activity relationship of substrate competitive, selective, and in vivo active triazole and thiadiazole inhibitors of the c-Jun N-terminal kinase. *J Med Chem.* 2009 Apr 9;52(7):1943-52.
- Augustine C, et al. Traumatic injury elicits JNK-mediated human astrocyte retraction in vitro. *Neuroscience.* 2014 Aug 22;274:1-10.
- Serizawa F, et al. Pretreatment of human cerebrovascular endothelial cells with CO-releasing molecule-3 interferes with JNK/AP-1 signaling and suppresses LPS-induced proadhesive phenotype. *Microcirculation.* 2015 Jan;22(1):28-36.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481